{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:19:59Z","timestamp":1791814799279,"version":"4.3.4"},"reference-count":37,"publisher":"Becaris Publishing Limited","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To evaluate the cost\u2013effectiveness of intravenous ferric carboxymaltose (FCM) versus placebo for the management of iron deficiency in patients with chronic heart failure in the Italian healthcare system and to estimate its impact on the national healthcare budget.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A Markov model was developed to project costs and health outcomes over 1\u00a0year, based on data from literature. Healthcare resources consumption was derived from an e-survey administered to clinicians. Costs were obtained from official tariffs.\n            <jats:bold>Results:<\/jats:bold>\n            Treatment with FCM represents a dominant strategy compared with placebo, leading to national budget annual savings of 20\u201397\u00a0million Euros, according to different increasing utilization rates.\n            <jats:bold>Conclusion:<\/jats:bold>\n            FCM is a cost-saving option for the treatment of chronic heart failure patients with iron deficiency in Italy.\n          <\/jats:p>","DOI":"10.2217\/cer-2019-0074","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T14:09:56Z","timestamp":1570111796000},"page":"1099-1110","source":"Crossref","is-referenced-by-count":18,"title":["Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost\u2013effectiveness and budget impact"],"prefix":"10.57264","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6330-0591","authenticated-orcid":false,"given":"Carla","family":"Rognoni","sequence":"first","affiliation":[{"name":"Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, 20136 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Gerzeli","sequence":"additional","affiliation":[{"name":"Department of Political and Social Sciences, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_6_3_2","unstructured":"Ministero della Salute (2019). http:\/\/www.salute.gov.it\/portale\/salute\/p1_5.jsp?lingua=italiano&id=43&area=Malattie_cardiovascolari"},{"issue":"2","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ehf2.12021","article-title":"Improving care for patients with acute heart failure: before, during and after hospitalization","volume":"1","author":"Cowie MR","year":"2014","unstructured":"Cowie MR , Anker SD , Cleland JGF Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 1(2), 110\u2013145 (2014).","journal-title":"ESC Heart Fail."},{"issue":"1","key":"e_1_3_6_5_2","first-page":"e6","article-title":"Heart disease and stroke statistics \u2013 2013 update: a report from the American Heart Association","volume":"127","author":"Go AS","year":"2013","unstructured":"Go AS , Mozaffarian D , Roger VL Heart disease and stroke statistics \u2013 2013 update: a report from the American Heart Association. Circulation 127(1), e6\u2013e245 (2013).","journal-title":"Circulation"},{"issue":"7","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni AP","year":"2013","unstructured":"Maggioni AP , Dahlstr\u00f6m U , Filippatos G EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur. J. Heart Fail. 15(7), 808\u2013817 (2013).","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"e_1_3_6_7_2","first-page":"575.e3","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip IT","year":"2013","unstructured":"Klip IT , Comin-Colet J , Voors AA Iron deficiency in chronic heart failure: an international pooled analysis. Am. Heart J. 165(4), 575.e3\u2013582.e3 (2013).","journal-title":"Am. Heart J."},{"issue":"11","key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","article-title":"Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives","volume":"34","author":"Jankowska EA","year":"2013","unstructured":"Jankowska EA , von Haehling S , Anker SD Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur. Heart J. 34(11), 816\u2013829 (2013).","journal-title":"Eur. Heart J."},{"issue":"12","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival","volume":"58","author":"Okonko DO","year":"2011","unstructured":"Okonko DO , Mandal AK , Missouris CG Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J. Am. Coll. Cardiol. 58(12), 1241\u20131251 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski P","year":"2015","unstructured":"Ponikowski P , van Veldhuisen DJ , Comin-Colet J Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J. 36, 657\u2013668 (2015).","journal-title":"Eur. Heart J."},{"issue":"7","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/eurjhf\/hfs083","article-title":"Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK","volume":"14","author":"Gutzwiller FS","year":"2012","unstructured":"Gutzwiller FS , Schwenkglenks M , Blank PR Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur. J. Heart Fail. 14(7), 782\u2013790 (2012).","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/eurjhf\/hft083","article-title":"Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status","volume":"15","author":"Com\u00edn-Colet J","year":"2013","unstructured":"Com\u00edn-Colet J , Enjuanes C , Gonz\u00e1lez G Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur. J. Heart Fail. 15(10), 1164\u20131172 (2013).","journal-title":"Eur. J. Heart Fail."},{"key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker SD","year":"2009","unstructured":"Anker SD , Comin Colet J , Filippatos G Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 2436\u20132448 (2009).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_14_2","first-page":"ii71","article-title":"The safety of intravenous (IV) ferric carboxymaltose versus IV iron sucrose on patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficiency (ID)","volume":"8","author":"Arutyunov G","year":"2009","unstructured":"Arutyunov G . The safety of intravenous (IV) ferric carboxymaltose versus IV iron sucrose on patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficiency (ID). Eur. J. Heart Fail. 8, ii71 (2009).","journal-title":"Eur. J. Heart Fail."},{"key":"e_1_3_6_15_2","unstructured":"Effect of ferric carboxymaltose on exercise capacity and cardiac function in patients with iron deficiency and chronic heart failure (EFFICACY-HF) (data on file). US National Institutes of Health (2009). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00821717"},{"issue":"27","key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P , Voors AA , Anker SD 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37(27), 2129\u20132200 (2016).","journal-title":"Eur. Heart J."},{"issue":"3","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ehf2.12179","article-title":"Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany","volume":"4","author":"Theidel U","year":"2017","unstructured":"Theidel U , V\u00e4\u00e4t\u00e4inen S , Martikainen J , Soini E , Hardt T , Doehner W . Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC Heart Fail. 4(3), 274\u2013281 (2017).","journal-title":"ESC Heart Fail."},{"issue":"1","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker SD","year":"2018","unstructured":"Anker SD , Kirwan BA , van Veldhuisen DJ Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur. J. Heart Fail. 20(1), 125\u2013133 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) \u2013 explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force","volume":"16","author":"Husereau D","year":"2013","unstructured":"Husereau D , Drummond M , Petrou S Consolidated health economic evaluation reporting standards (CHEERS) \u2013 explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 16, 231\u2013250 (2013).","journal-title":"Value Health"},{"issue":"1","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan SD","year":"2014","unstructured":"Sullivan SD , Mauskopf JA , Augustovski F Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 17(1), 5\u201314 (2014).","journal-title":"Value Health"},{"issue":"4","key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eujim.2015.07.002","article-title":"Delphi methodology in health research: how to do it?","volume":"7","author":"Esm\u00e9 G","year":"2015","unstructured":"Esm\u00e9 G , Trevelyan J , Robinson C . Delphi methodology in health research: how to do it? Eur. J. Integr. Med. 7(4), 423\u2013428 (2015).","journal-title":"Eur. J. Integr. Med."},{"key":"e_1_3_6_22_2","unstructured":"La rete cardiologica per la cura del malato con scompenso cardiaco: organizzazione dell'assistenza ambulatoriale (2016). http:\/\/www.anmco.it\/uploads\/u_cms\/media\/2016\/6\/69730b48ccd65dce09bf23dae9ef32fb.pdf"},{"key":"e_1_3_6_23_2","unstructured":"Federfarma (2019). http:\/\/www.federfarma.it"},{"issue":"2","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40292-017-0193-4","article-title":"The burden of chronic heart failure in primary care in Italy","volume":"24","author":"Piccinni C","year":"2017","unstructured":"Piccinni C , Antonazzo IC , Simonetti M The burden of chronic heart failure in primary care in Italy. High Blood Press. Cardiovasc. Prev. 24(2), 171\u2013178 (2017).","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"e_1_3_6_25_2","unstructured":"D'ambrosio\n                            G\n                    . La gestione dei pazienti con scompenso cardiaco in Medicina Generale: i risultati preliminari di un audit condotto per via telematica. Esperienze e ricerche in Medicina Generale. Societ\u00e0 Italiana di Medicina Generale. Rivista della Societ\u00e0 Italiana di Medicina Generale. N.4 AgostoAugust 2010 (2010). https:\/\/www.simg.it\/documenti\/rivista\/2010\/04_2010\/3.pdf"},{"issue":"6","key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00392-016-1073-y","article-title":"Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry","volume":"106","author":"von Haehling S","year":"2017","unstructured":"von Haehling S , Gremmler U , Krumm M Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry. Clin. Res. Cardiol. 106(6), 436\u2013443 (2017).","journal-title":"Clin. Res. Cardiol."},{"issue":"2","key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7175\/fe.v4i2.773","article-title":"Durata e costo delle visite in medicina generale: il progetto DYSCO. (Duration and cost of GP visits)","volume":"4","author":"Garattini L","year":"2003","unstructured":"Garattini L , Castelnuovo E , Lanzeni D , Viscarra C . Durata e costo delle visite in medicina generale: il progetto DYSCO. (Duration and cost of GP visits). Farmeconomia e percorsi terapeutici 4(2), 109\u2013114 (2003).","journal-title":"Farmeconomia e percorsi terapeutici"},{"issue":"24","key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/eurheartj\/ehi662","article-title":"Cost\u2013effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial","volume":"26","author":"Calvert MJ","year":"2005","unstructured":"Calvert MJ , Freemantle N , Yao G Cost\u2013effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur. Heart J. 26(24), 2681\u20132688 (2005).","journal-title":"Eur. Heart J."},{"issue":"2","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/(SICI)1099-1050(200003)9:2<149::AID-HEC501>3.0.CO;2-N","article-title":"Establishing health state valuations for disease specific states: an example from heart disease","volume":"9","author":"Kirsch J","year":"2000","unstructured":"Kirsch J , McGuire A . Establishing health state valuations for disease specific states: an example from heart disease. Health Econ. 9(2), 149\u2013158 (2000).","journal-title":"Health Econ."},{"issue":"13","key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/heartjnl-2013-304598","article-title":"The cost\u2013effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective","volume":"100","author":"Griffiths A","year":"2014","unstructured":"Griffiths A , Paracha N , Davies A The cost\u2013effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart 100(13), 1031\u20131036 (2014).","journal-title":"Heart"},{"issue":"1","key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1524-4733.2008.00425.x","article-title":"Utility estimates for decision-analytic modeling in chronic heart failure \u2013 health states based on New York Heart Association classes and number of rehospitalizations","volume":"12","author":"G\u00f6hler A","year":"2009","unstructured":"G\u00f6hler A , Geisler BP , Manne JM Utility estimates for decision-analytic modeling in chronic heart failure \u2013 health states based on New York Heart Association classes and number of rehospitalizations. Value Health 12(1), 185\u2013187 (2009).","journal-title":"Value Health"},{"issue":"9","key":"e_1_3_6_32_2","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1053-2498(01)00298-4","article-title":"Preferences for quality of life or survival expressed by patients with heart failure","volume":"20","author":"Lewis EF","year":"2001","unstructured":"Lewis EF , Johnson PA , Johnson W Preferences for quality of life or survival expressed by patients with heart failure. J. Heart Lung Transplant. 20(9), 1016\u20131024 (2001).","journal-title":"J. Heart Lung Transplant."},{"issue":"2","key":"e_1_3_6_33_2","first-page":"106","article-title":"Cost\u2013effectiveness of telephonic disease management in heart failure","volume":"14","author":"Smith B","year":"2008","unstructured":"Smith B , Hughes-Cromwick PF , Forkner E , Galbreath AD . Cost\u2013effectiveness of telephonic disease management in heart failure. Am. J. Manag. Care 14(2), 106\u2013115 (2008).","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski P","year":"2014","unstructured":"Ponikowski P , Anker SD , AlHabib KF Heart failure: preventing disease and death worldwide. ESC Heart Fail. 1, 4\u201325 (2014).","journal-title":"ESC Heart Fail."},{"issue":"10","key":"e_1_3_6_35_2","first-page":"846","article-title":"A cost\u2013effectiveness analysis of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Spain","volume":"68","author":"Com\u00edn-Colet J","year":"2015","unstructured":"Com\u00edn-Colet J , Rubio-Rodr\u00edguez D , Rubio-Terr\u00e9s C A cost\u2013effectiveness analysis of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Spain. Rev. Esp. Cardiol. (Engl. Ed.) 68(10), 846\u2013851 (2015).","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"issue":"7","key":"e_1_3_6_36_2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3111\/13696998.2015.1029491","article-title":"Cost\u2013effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden","volume":"18","author":"Hofmarcher T","year":"2015","unstructured":"Hofmarcher T , Borg S . Cost\u2013effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J. Med. Econ. 18(7), 492\u2013501 (2015).","journal-title":"J. Med. Econ."},{"issue":"6","key":"e_1_3_6_37_2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/14017431.2018.1546894","article-title":"Cost\u2013effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries","volume":"52","author":"Hofmarcher T","year":"2018","unstructured":"Hofmarcher T , Cabrales Alin D , Linde C . Cost\u2013effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries. Scand. Cardiovasc. J. 52(6), 348\u2013355 (2018).","journal-title":"Scand. Cardiovasc. J."},{"key":"e_1_3_6_38_2","unstructured":"European Network for Health Technology Assessment (EUnetHTA) (2019). www.eunethta.eu"},{"issue":"23","key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"pii: 124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf M","year":"2018","unstructured":"Wolf M , Chertow GM , Macdougall IC Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 3(23), pii: 124486 (2018).","journal-title":"JCI Insight"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2019-0074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:46:03Z","timestamp":1679229963000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2019-0074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.2217\/cer-2019-0074"],"URL":"https:\/\/doi.org\/10.2217\/cer-2019-0074","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}